Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CLNN
#4129
Clene Inc. Common Stock
6.570
0
USD
+1.39%
Sector:
Consumer Defensive
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.39%
Monthly Change
+15.26%
6 month change
+46.98%
Year Change
+46.98%
Previous Close
6.480
0
Open
6.615
0
Bid
Ask
Low
6.570
0
High
6.650
0
Volume
3
Markets
US Stock Market
Consumer Defensive
CLNN
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
2.98 M
3.16 M
3.85 M
6.42 M
8.59 M
11.78 M
—
Valuation ratios
Enterprise value
480.98 M
217.84 M
76.7 M
31.33 M
44 M
85.79 M
254.61 M
Price to earnings ratio
-9.73
-9.62
-2.07
-0.62
-0.94
-2.21
-5.54
Price to sales ratio
910.51
129.66
130.97
47.17
107.97
289.36
680.11
Price to cash flow ratio
-9.91
-2.71
-1.59
-1.02
-1.73
-3.12
-8.81
Price to book ratio
550.04
7.44
19.14
2.3
-4.17
-3.29
-7.19
Enterprise value to EBITDA ratio
-25.25
-4.29
-3.5
-0.81
-3.38
-9.76
-22.02
Profitability ratios
Return on assets %
-0.28
-0.15
-0.67
-0.95
-1.44
-1.44
-1.27
Return on equity %
-56.53
-0.77
-9.24
-3.7
4.45
1.49
2.25
Return on invested capital %
-637.21
-1 605.31
-1 167.4
-580.46
-574.78
-696.82
-726.2
Gross margin %
100
100
94.5
81.5
79.53
78.5
345.44
Operating margin %
-9 812.62
-6 912.59
-10.23 K
-6 198.78
-9 676.32
-11.54 K
-74.14 K
EBITDA margin %
-9 173.3
-6 722.68
-3 303.59
-1 686.54
-2 889.47
-3 275
-20.7 K
Net margin %
-9 357.77
-1 347.16
-6 325.16
-7 569.42
-11.52 K
-13.09 K
-98.9 K
Liquidity ratios
Quick ratio
5.38
9.05
2.1
1.53
1.56
0.83
5.28
Current ratio
5.4
9.06
2.11
1.53
1.57
0.83
5.3
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.01
0.01
0.01
0.01
0.01
0.01
Solvency ratios
Debt to assets ratio
0.06
0.15
0.49
0.43
0.39
1.2
4.01
Debt to equity ratio
11.52
0.74
6.78
1.67
-1.19
-1.24
-9.84
Long term debt to total assets ratio
0.03
0.07
0.36
0.32
0.2
0.98
3.18
Long term debt to total equity ratio
5.72
0.37
4.91
1.26
-0.62
-1.01
-7.73
Per share metrics
Operating cash flow per share
-18.19
-30.29
-11.97
-5.75
-3.07
-1.88
-1.94
EBIT per share
-19.42
-43.72
-14.85
-7.73
-4.76
-2.34
-2.39
EBITDA per share
-18.16
-42.52
-4.79
-2.1
-1.42
-0.66
-0.69
Total debt per share
3.77
8.15
6.73
4.27
1.52
2.22
9.03
Cash per share
56.95
44.04
7.15
6.67
1.75
0.53
3.17
Net current asset value per share
60.52
47.75
8.95
7.4
2.32
0.91
5.06
Tangible book value per share
0.33
11.02
0.99
2.55
-1.27
-1.78
-4.45
Working capital per share
49.31
42.48
4.7
2.58
0.84
-0.18
1.15
Book value per share
0.33
11.02
0.99
2.55
-1.27
-1.78
-4.45
News
Clene Inc. ten percent owner sells $161k in shares
Clene Inc. ten percent owner sells $256k in shares
FDA grants Clene in-person meeting to discuss ALS drug biomarker data
Clene secures $28 million in registered direct offering for ALS drug
Clene Inc. ten percent owner Ugwumba sells $78k in shares
Ugwumba Chidozie sells Clene Inc. (CLNN) stock worth $73,123
Clene Inc: Ugwumba sells $73k in CLNN stock
Benchmark reiterates Buy rating on Clene stock amid positive biomarker data
Clene stock holds Buy rating at Benchmark as ALS drug nears FDA submission
Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates